Tafamidis Reduces Mortality Rates In Cardiomyopathy Patients Overview The study explored the effectiveness of tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) across varying levels of left ventricular ejection fraction (LVEF). Conducted as part of the phase 3 ATTR-ACT trial and its subsequent long-term extension (LTE) study, patients were initially randomized to
Tag: Tafamidis
